Boundless Bio, Inc. BOLD 深 滬
已收盤 09-26 16:00:00 美东时间
1.14
+0.010
+0.88%
華盛通- 最 高1.16
- 今 開1.16
- 成交量 10.69万股
- 最 低 1.11
- 昨 收 1.13
- 總市值 2551.96万
- 52周最高 3.75
- 市盈率 靜 --
- 換手率 0.48%
- 52周最低 1.00
- 委 比 -73.13%
- 總股本 2238.56万
- 歷史最高 15.24
- 量 比 1.23
- 振 幅 4.42%
- 歷史最低 1.00
- 每 手 1
- 風險率 0.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Paramount Marks Star Trek's 60th Anniversary With Rose Parade Debut, Starfleet Academy Series, Cruise Experience
Paramount Skydance is celebrating Star Trek's 60th anniversary in 2026 with a yearlong lineup that includes new shows, a Rose Parade float.
09-10 18:09
Henry Schein Authorizes $750M Share Repurchase Plan
Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care products and services to office-based dental and medical practitioners, announced today that its Board of Directors has authorized the
09-10 05:13
CHEEZ-IT® REINVENTS SNACKING WITH ALL-NEW CHEEZ-IT CRUNCH: DELIVERING MAX CRUNCH AND BOLD FLAVOR LIKE NEVER BEFORE
The brand's biggest innovation in three years is perfectly designed to deliver a flavor-forward, crunchy snacking experience Key News Bites Cheez-It® debuts new Cheez-It Crunch lineup combin...
09-08 20:00
BLOOMINGDALE'S UNVEILS BOLD FALL 2025 CAMPAIGN: JUST IMAGINE
An immersive celebration of art, identity, and modern retail arrives this fall at Bloomingdale's 59th Street flagship—featuring a striking façade and Carousel takeover, designed by acclaimed...
09-04 21:00
Praxis Precision Medicines To Present 12 Epilepsy Pipeline Updates, Including RADIANT Results, At IEC 2025 In Lisbon
Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced its participation in the upcoming
08-26 04:02
HC Wainwright & Co. Maintains Buy on Boundless Bio, Lowers Price Target to $4
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Boundless Bio (NASDAQ:BOLD) with a Buy and lowers the price target from $5 to $4.
08-11 18:43
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
Boundless Bio has announced its Q2 2025 financial results, including $127 million in cash, and highlighted progress in its oncology programs. The POTENTIATE trial's BBI-355/BBI-825 combination arm is now open for enrollment, and BBI-940 is on track for IND submission in H1 2026. The company aims to deliver proof-of-concept data for both programs within its current cash runway, supporting operations into H1 2028. R&D expenses were $12.2 million, a...
08-05 11:00
Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures
Praxis Precision Medicines stock fluctuated after reporting mixed results for their drug vormatrigine in treating focal onset seizures.
08-05 01:38
重新审视稳定币的三难困境：当前去中心化的衰落
文章来源：Odaily星球日报 原文作者：Chilla 原文编译：Block unicorn 前言 稳定币备受关注，这并非无故。它除了投机之...
06-30 20:00
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology, announced that President and CEO Zachary Hornby will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, in Miami, FL. The session will be live and archived on the company’s Investor Relations website. Boundless Bio is developing ecDNA-directed therapeutic candidates to address ...
06-05 20:58
